Search results
Found 8426 matches for
Paper by NJ White et al, PLoS Medicine, in press. Using available pharmacokinetic information from healthy volunteers, the treatment of malaria, the chronic treatment of rheumatological conditions and the toxicokinetics of chloroquine in self-poisoning, the authors predict exposures and safety margins in the high dose chloroquine and hydroxychloroquine COVID-19 prevention and treatment regimens currently under evaluation. These regimens are predicted to have reasonable safety margins. Large, well conducted randomised clinical trials with appropriate monitoring are required to determine if chloroquine and hydroxychloroquine have preventive or treatment efficacy in COVID-19 and acceptable safety. Current recommendations for their use outside of clinical trials are not justified at this time.
Nicholas White
COVID-19 Investigators Principal Investigators Research Scientists
FRS Nicholas White - Professor of Tropical Medicine
Naomi Waithira
COVID-19 Investigators Graduate Students Research Scientists
Naomi Waithira - MORU head of Data Management
Kevin Kobylinski
Research Scientists
Kevin Kobylinski - Honorary Visiting Research Fellow in Medical Entomology
Steeve Ebener
Research Scientists
Steeve Ebener - Health Geolab Coordinator and Technical Assistance Lead